Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who used semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the ...

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

A wave of public alarm over counterfeit and dangerous foreign-made prescription drugs, particularly from China, has reached new heights, according to a recent ...